U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer
− Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior…
− Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior…
MONTREAL--(BUSINESS WIRE)--The International Federation of Air Line Pilots’ Associations (IFALPA) is closely monitoring the developments…
SHANGHAI--(BUSINESS WIRE)--OCO Global, a leading specialist trade and investment advisory firm has today announced the…
The plant in Japan marks a milestone event for Fresh Del Monte Produce, showcasing the…
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical…
LONDON--(BUSINESS WIRE)--#CompetitiveIntelligence--Infiniti Research is a leading provider of market intelligence services to businesses around the…
BEIJING--(BUSINESS WIRE)--New Frontier Health Corporation (“NFH” or “the Company”) (NYSE: NFH), operator of the premium…
First-in-human phase 1 trial initiated with DS-6157, a GPR20 directed ADC, in patients with advanced…
NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Jefferies announced today that it will hold a…
HANGZHOU, China--(BUSINESS WIRE)--Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988, “Alibaba” or “Alibaba Group”)…